TheEdgeResearch
Home / Stocks / ASND

Ascendis Pharma A/S (ASND)

NASDAQ Healthcare Biotechnology
$252.73 ▼ -1.26%
Market Cap
$16.58B
Sector
Healthcare
Industry
Biotechnology
Beta
0.40
52-Wk Range
188.08-282.15
CEO
Jan Moller Mikkelsen
Country
DK
Currency
USD

Ascendis Pharma A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Hellerup, CR, DK. The stock last traded at $252.73, down 1.26% on the session, giving a market capitalisation of $16.58B. On trailing twelve-month figures it carries a trailing P/E of 16.21, a net margin of 73.7%. Its beta of 0.40 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
16.21
Price / Sales
12.51
Price / Book
10.10
EV / EBITDA
56.16
Gross margin
90.6%
Operating margin
18.4%
Net margin
73.7%
Return on equity
—
Debt / equity
0.30
Current ratio
2.89
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
1,189
IPO date
2015-01-28
Headquarters
Hellerup, CR, DK
About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Comparable companies

Ascendis Pharma A/S is most often compared with the following Healthcare names:

BMRNCORTINSMMBXNBIXRARESEPNSTOKUTHRXERS
More research on ASND
ASND technical analysis ASND TheEdge Score Compare against peers
Open full interactive analysis & DCF →